Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
207.2 INR | +3.83% | +8.45% | -0.07% |
01-18 | Nath Bio-Genes Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
2023 | Transcript : Nath Bio-Genes Limited, Q2 2024 Earnings Call, Oct 17, 2023 |
Sales 2022 | 2.78B 33.39M 45.65M | Sales 2023 | 3.01B 36.15M 49.42M | Capitalization | 2.68B 32.2M 44.02M |
---|---|---|---|---|---|
Net income 2022 | -673M -8.07M -11.04M | Net income 2023 | 350M 4.2M 5.74M | EV / Sales 2022 | 1.78 x |
Net Debt 2022 | 888M 10.65M 14.56M | Net Debt 2023 | 672M 8.06M 11.02M | EV / Sales 2023 | 1.11 x |
P/E ratio 2022 |
-6.02
x | P/E ratio 2023 |
7.67
x | Employees | 433 |
Yield 2022 |
0.94% | Yield 2023 |
1.42% | Free-Float | 38.47% |
Latest transcript on Nath Bio-Genes (India) Limited
1 day | +3.83% | ||
1 week | +8.45% | ||
Current month | +19.25% | ||
1 month | +19.25% | ||
3 months | -4.93% | ||
6 months | +11.64% | ||
Current year | -0.07% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 99-08-29 | |
Director of Finance/CFO | 63 | - | |
Compliance Officer | 30 | 18-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 99-08-29 | |
Director/Board Member | 60 | 12-10-09 | |
Director/Board Member | 42 | 15-03-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 207.2 | +3.83% | 8,717 |
24-04-25 | 199.6 | +0.33% | 877 |
24-04-24 | 198.9 | -0.82% | 2,765 |
24-04-23 | 200.6 | +1.19% | 2,542 |
24-04-22 | 198.2 | +3.74% | 5,788 |
Delayed Quote Bombay S.E., April 26, 2024 at 06:21 am
More quotes1st Jan change | Capi. | |
---|---|---|
+12.78% | 3.29B | |
-95.58% | 1.61B | |
-0.48% | 1.61B | |
-2.37% | 1.25B | |
-2.40% | 1.22B | |
-.--% | 1.22B | |
-11.54% | 1.21B | |
-10.44% | 1.2B | |
0.00% | 1.19B |
- Stock Market
- Equities
- NATHBIOGEN Stock
- 537291 Stock